Senotherapies fall into six strategies: palbociclib arrests tumor growth and suppresses inflammation in the aged liver
Senotherapies fall into six strategies: palbociclib arrests tumor growth and suppresses inflammation in the aged liver
On 13 September 2026, the Immortalist’s Handbook 2.0 channel proposed its own classification of six ways to target senescent cells. Primary sources support these approaches, although some describe biological mechanisms and others describe ways to deliver treatment precisely. Where a drug fits in this classification depends on the tissue and the treatment goal.
Senescent cells stop dividing and can release substances that sustain inflammation. Senolytics kill these cells. Navitoclax blocks BCL-xL, a protein that helps senescent cells survive. Platelets also depend on this protein, so the drug can impair blood clotting.
This toxicity prompted researchers to pursue more targeted ways to kill senescent cells using antibodies, nanoparticles, and CAR-T cells, which are T cells with an engineered receptor. Anti-uPAR CAR-T cells recognize a marker found on some senescent cells. In 2026, they improved intestinal regeneration in aged mice; this line of research began in 2020 with a model of liver fibrosis.
A 2024 review used the term senoblockers for agents that prevent cells from entering senescence and senoreversers for agents that reverse this state. Senomorphics have a different action: rapamycin and metformin suppress inflammatory signals from senescent cells while maintaining their growth arrest.
In oncology, senescence is also used to slow tumor growth. Chemotherapy, radiation, and CDK4/6 inhibitors, drugs that inhibit cell division and include palbociclib, induce sustained growth arrest in tumor cells. A 2026 review describes an experimental “one-two punch” approach: after the first treatment, a senolytic or an immune-based intervention removes the senescent cells. In aged mice, the same drug, palbociclib, suppressed inflammatory signaling from cells in the liver that were already senescent and improved motor coordination.
Ibrutinib provides another example of a drug taking on a different role. It is used to treat chronic lymphocytic leukemia and mantle cell lymphoma; by blocking the kinase BTK, it reduces the activity of p53, a protein that triggers senescence. In mice with progeria, a genetic model of accelerated aging, ibrutinib increased maximum lifespan, reduced frailty, and preserved spatial memory.
The word “senoptosis” refers to different processes in a research paper and an indexing vocabulary. In 2017, German biologists used “senoptosis” to describe an irradiated cell’s progression into deep senescence: the enzyme EndoG cleaves DNA, but the cell remains alive and no longer divides. In the 2022 MeSH thesaurus, “senoptosis inducers” are agents that eliminate senescent cells. The same word thus refers both to a cell entering senescence and to its elimination.